volume of 11.4 mL; dilute requisite dose in 100 mL of Glucose 5% or Sodium chloride 0.9%; give over 1 hour.

- **HANDLING AND STORAGE** Manufacturer advises store in a refrigerator at 2°C–8°C.
- **PATIENT AND CARER ADVICE**

Driving and skilled tasks Manufacturer advises ceftolozane with tazobactam may influence driving and performance of skilled tasks—increased risk of dizziness.

- **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) decisions
SMC No. 1146/16
The *Scottish Medicines Consortium* has advised (May 2016) that ceftolozane with tazobactam (*Zerbaxa*®) is **not** recommended for use within NHS Scotland for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and acute pyelonephritis as the clinical and economic case was not demonstrated.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion
ELECTROLYTES: May contain Sodium
- Zerbaxa (Merck Sharp & Dohme Ltd) ▼
  Tazobactam (as Tazobactam sodium) 500 mg, Ceftolozane (as Ceftolozane sulfate) 1 gram Zerbaxa 1g/0.5g powder for concentrate for solution for infusion vials | 10 vial PoM £670.30 (Hospital only)

ANTIBACTERIALS › CEPHALOSPORINS, OTHER

F 550

Cefepime

12-Dec-2019

- **INDICATIONS AND DOSE**

Infections due to sensitive Gram-positive and Gram-negative bacteria
- BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION, OR BY INTRAMUSCULAR INJECTION
- Adult (body-weight up to 41 kg): 50 mg/kg every 12 hours (max. per dose 2 g), increased if necessary to 50 mg/kg every 8 hours (max. per dose 2 g), increased dose used for severe infections, intravenous route preferred in severe infections

Mild to moderate urinary tract infections
- BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION, OR BY INTRAMUSCULAR INJECTION
- Adult (body-weight 41 kg and above): 0.5–1 g every 12 hours

Mild to moderate infections due to sensitive Gram-positive and Gram-negative bacteria
- BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION, OR BY INTRAMUSCULAR INJECTION
- Adult (body-weight 41 kg and above): 1 g every 12 hours

Severe infections due to sensitive Gram-positive and Gram-negative bacteria
- BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
- Adult (body-weight 41 kg and above): 2 g every 12 hours, increased if necessary to 2 g every 8 hours, increased dose used for very severe infections

- **INTERACTIONS** → Appendix 1: cephalosporins
- **SIDE-EFFECTS**
- **Common or very common** Anaemia
- **Uncommon** Gastrointestinal disorders · increased risk of infection
- **Rare or very rare** Constipation · dyspnoea · genital pruritus · paraesthesia · seizure · taste altered · vasodilation
- **Frequency not known** Anaphylactic shock · aplastic anaemia · coma · confusion · consciousness impaired · encephalopathy · haemorrhage · hallucination · myoclonus · nephrotoxicity · renal failure
- **PREGNANCY** Manufacturer advises caution—no data available but not known to be harmful in *animal* studies.
- **BREAST FEEDING** Manufacturer advises caution—present in milk in very low quantities.
- **RENAL IMPAIRMENT** Manufacturer advises use with caution.
  Dose adjustments Manufacturer advises reduce dose—consult product literature.
- **DIRECTIONS FOR ADMINISTRATION** After reconstitution the solution is yellow to yellow-brown. Displacement value may be significant when reconstituting injection, consult local guidelines. For *intravenous infusion*, manufacturer advises reconstitute with 50 mL Glucose 5% or 10% *or* Sodium Chloride 0.9%; give over 30 minutes. For *intravenous injection*, manufacturer advises reconstitute with 10 mL Glucose 5% or 10% *or* Sodium Chloride 0.9%. For *intramuscular injection*, manufacturer advises reconstitute with 3 mL Water for Injection.
- **NATIONAL FUNDING/ACCESS DECISIONS**

All Wales Medicines Strategy Group (AWMSG) decisions
AWMSG No. 4129
The *All Wales Medicines Strategy Group* has advised (November 2019) that cefepime (*Renapime*®) is recommended as an option for restricted use within NHS Wales. It should be restricted to use in the treatment of resistant pseudomonas infections where first-line agents are not effective or contra-indicated. It is not recommended for use within NHS Wales outside of this subpopulation.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection
- Renapime (Renascience Pharma Ltd)
  Cefepime (as Cefepime dihydrochloride monohydrate) 1 gram Renapime 1g powder for solution for injection vials | 10 vial PoM £70.00
  Cefepime (as Cefepime dihydrochloride monohydrate) 2 gram Renapime 2g powder for solution for injection vials | 10 vial PoM £110.00

F 550

Ceftaroline fosamil

21-May-2020

- **INDICATIONS AND DOSE**

Community-acquired pneumonia
- BY INTRAVENOUS INFUSION
- Adult: 600 mg every 12 hours for 5–7 days

Complicated skin infections | Complicated soft-tissue infections
- BY INTRAVENOUS INFUSION
- Adult: 600 mg every 12 hours for 5–14 days, for high dose regimen consult product literature

- **CAUTIONS** Seizure disorders
- **INTERACTIONS** → Appendix 1: cephalosporins
- **SIDE-EFFECTS**
- **Uncommon** Anaemia · antibiotic associated colitis · hypersensitivity
- **PREGNANCY** Manufacturer advises avoid unless essential—limited information; *animal* studies do not indicate toxicity.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **RENAL IMPAIRMENT**
  Dose adjustments Manufacturer advises reduce dose if creatinine clearance less than 51 mL/minute—consult product literature.